SOPH
NASDAQSOPHiA GENETICS SA
Price$6.75-0.39 (-5.46%)
01:45 PM07:45 PM
News · 26 weeks111+80%
2026-04-192026-10-11
Mix4590d
- Insider35(78%)
- SEC Filings4(9%)
- Other3(7%)
- Analyst1(2%)
- Earnings1(2%)
- Offering1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- PRSOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyBOSTON, Oct. 8, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ:MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (NYSE:AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions.Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, whe
- PRMyriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologySALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ:SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (NYSE:AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERSEC Form 4 filed by SOPHiA GENETICS SA4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- SECSEC Form 144 filed by SOPHiA GENETICS SA144 - SOPHiA GENETICS SA (0001840706) (Subject)
- INSIDERChief Executive Officer Muken Ross sold $3,515 worth of Ordinary Shares (422 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 0.06% to 670,229 units (SEC Form 4) to cover withholding tax4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Financial Officer Cardoza George sold $6,447 worth of Ordinary Shares (774 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 0.25% to 308,318 units (SEC Form 4) (for withholding tax)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- SECSEC Form 144 filed by SOPHiA GENETICS SA144 - SOPHiA GENETICS SA (0001840706) (Subject)
- INSIDERChief Medical Officer Menu Philippe sold $39,416 worth of Ordinary Shares (5,000 units at $7.88) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 208,387 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Scientific Officer Xu Zhenyu sold $31,538 worth of Ordinary Shares (4,000 units at $7.88) as part of a pre-agreed trading plan, decreasing direct ownership by 0.72% to 552,887 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERExecutive Chairman Camblong Jurgi sold $65,120 worth of Ordinary Shares (8,500 units at $7.66) as part of a pre-agreed trading plan, decreasing direct ownership by 0.25% to 3,435,822 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Legal Officer Van Well Daan sold $47,089 worth of Ordinary Shares (6,168 units at $7.63) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 338,884 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERDirector Hibbs Kathy L sold $50,818 worth of Ordinary Shares (6,250 units at $8.13) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 96,992 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Scientific Officer Xu Zhenyu sold $89,096 worth of Ordinary Shares (10,000 units at $8.91) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 556,887 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERDirector Hibbs Kathy L sold $54,233 worth of Ordinary Shares (6,250 units at $8.68) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 103,242 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
SOPH FAQ
7 questionsWhat does SOPHiA GENETICS SA do?
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.Where does SOPH stock trade?
SOPHiA GENETICS SA (SOPH) is listed on NASDAQ.What sector and industry is SOPH in?
SOPHiA GENETICS SA operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did SOPHiA GENETICS SA go public?
SOPHiA GENETICS SA (SOPH) completed its IPO in 2021.What are analysts saying about SOPH?
SOPHiA GENETICS SA has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2026-07-20.What companies are similar to SOPH?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SOPH side-by-side with any of them on Quantisnow.How can I track SOPH on Quantisnow?
Quantisnow aggregates SOPHiA GENETICS SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SOPH to receive live email and push alerts on every new disclosure.